Press releases

Press Releases

This section contains official press releases issued by Egetis. These announcements include regulatory updates, corporate developments and information disclosed in accordance with applicable market regulations.

Search below for our latest press releases and company reports

Corporate Information

International retrospective cohort study published on “molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)”

October 16, 2026

Regulatory Corporate Action

Changes in number of shares and votes in Egetis Therapeutics

September 30, 2026

Regulatory Corporate Information

Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency

September 28, 2026

Corporate Information

Emcitate® (tiratricol) Presentations at ETA and ESPE Congresses in September 2026

September 4, 2026

Corporate Information

Egetis Therapeutics to Participate in Upcoming Investor Conferences in September

September 3, 2026

Corporate Information

Egetis Therapeutics to Participate in Upcoming Investor Conferences in September

September 3, 2026

Corporate Information

Tiratricol Granted Orphan Drug Designation for MCT8 Deficiency in Japan

August 31, 2026

Regulatory Report

Egetis’ Interim report Q2 2026

August 21, 2026

Corporate Information

Invitation to Presentation of Egetis’ Q2 2026 Report on August 21, 2026

August 7, 2026

Corporate Information

Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency

June 10, 2026

Regulatory Corporate Action

Change in the number of shares and votes in Egetis Therapeutics

May 29, 2026

Corporate Information

Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026

May 19, 2026

For media or investor enquiries please contact:

[email protected] [email protected] +46 8 679 72 10

Latest From LinkedIn

Explore